March 18, 2008
Basilea Pharmaceutica announced today that the FDA has issued an approvable letter for its first-in-class anti-MRSA agent cephalosporin for which company sought an indication to treat skin infections and diabetic foot infections. According to the company, prior to approval the … Continue reading →
Last week, the FDA offered testimony before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations regarding food safety delivered by Stephen F. Sundlof, DVM, PhD, Director at the Center for Food Safety and Applied Nutrition. It … Continue reading →